Compare Palantir Technologies Inc (PLTR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Smith & Nephew plc — how do they compare? Palantir Technologies Inc trades at $124.8 (market cap $318.03B), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Palantir Technologies Inc is far larger — about 25× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.59% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | SNN | |
|---|---|---|
Market Cap | $318.03B | $12.71B |
Sector | Technology | Health |
52-Week High | $207.18 | $38.70 |
52-Week Low | $107.27 | $28.73 |
Enterprise Value | $310.21B | $15.48B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $132.62, up 0.18% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.33 exceeding expectations. Revenue grew to $4.48 billion in 2025, and net income surged to $1.63 billion, reflecting robust profitability. Analyst sentiment is mixed, with a consensus price target of $185.75 and 46% of analysts rating it a Buy.
Outlook: PLTR's accelerating revenue growth and expanding margins support long-term upside, but high valuation multiples (P/E 151.52, P/S 66.33) pose risks if growth slows. Key catalysts include continued AI adoption and execution on guidance. Risks include competitive pressures and market volatility. The stock offers growth potential but requires tolerance for premium valuation and earnings sensitivity.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
